Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 3/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374625 | 1.00 | SLC7A5 (0.47) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL20494781 | 0.82 | SLC7A5 (0.55) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL1081375 | 0.79 | SLC7A5 (0.51) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL1081374 | 0.79 | SLC7A5 (0.51) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL27669804 | 0.79 | SLC7A5 (0.51) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL5137034 | 0.78 | SLC7A5 (0.47) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL5137033 | 0.78 | SLC7A5 (0.47) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL2542276 | 0.76 | SLC7A5 (0.56) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL2986794 | 0.76 | SLC7A5 (0.56) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL22462013 | 0.76 | SLC7A5 (0.49) | SLC7A5ESR1ESR2POLBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130022999-A1 | PROTEIN FRAGMENT COMPLEMENTATION ASSAYS FOR THE DETECTION OF BIOLOGICAL OR DRUG INTERACTIONS | ODYSSEY PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8192944-B2 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY THERA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110287950-A1 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7989218-B2 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY THERA INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1027608-B1 | PROTEIN FRAGMENT COMPLEMENTATION ASSAYS | ODYSSEY THERA INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20080145315-A1 | Protein fragment complementation assays in whole animals applications to drug efficacy, adme, cancer biology, immunology, infectious disease and gene therapy | ODYSSEY PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-7306914-B2 | Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy | ODYSSEY THERA INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070148682-A1 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-7160691-B2 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY THERA INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-0966685-B9 | PROTEIN FRAGMENT COMPLEMENTATION ASSAYS TO DETECT BIOMOLECULAR INTERACTIONS | ODYSSEY THERA INC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050079547-A1 | Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy | MICHNICK STEPHEN WILLIAM WATSO (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20040038298-A1 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030049688-A1 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY PHARMACEUTICALS, INC. | 2003-03-13 | — | — | US | disclosed |
| US-6428951-B1 | COMPRISING REASSEMBLY OF SEPARATE FRAGMENTS OF MONOMERIC ENZYME WHEREIN REASSEMBLY OF MONOMERIC ENZYME FRAGMENTS IS OPERATED BY INTERACTION OF MOLECULAR DOMAINS FUSED TO EACH MONOMERIC ENZYME FRAGMENT | ODYSSEY PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| US-6294330-B1 | SCREENING LIGANDS OF CELLULAR RECEPTOR BY GENERATING VECTORS ENCODING FUSION PROTEINS OF FRAGMENTS OF REPORTER MOLECULE AND SUBDOMAINS OF RECEPTOR, TRANSFECTING CELLS WITH VECTORS, TESTING CELLS FOR REPORTER MOLECULE ACTIVITY | ODYSSEY PHARMACEUTICALS INC. | 2001-09-25 | — | — | US | disclosed |
| US-6270964-B1 | POLYPEPTIDE USED A DIAGNOSTIC TOOL IN GENETIC ENGINEERING | ODYSSEY PHARMACEUTICALS INC. | 2001-08-07 | — | — | US | disclosed |
| EP-1027608-A2 | PROTEIN FRAGMENT COMPLEMENTATION ASSAYS | UNIVERSITE DE MONTREAL (CA) | 2000-08-16 | — | — | EP | disclosed |
| WO-2000007038-A2 | PROTEIN FRAGMENT COMPLEMENTATION ASSAYS | UNIVERSITE DE MONTREAL (CA) | 2000-02-10 | — | — | WO | disclosed |
| EP-0966685-A1 | PROTEIN FRAGMENT COMPLEMENTATION ASSAYS TO DETECT BIOMOLECULAR INTERACTIONS | UNIVERSITE DE MONTREAL (CA) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998034120-A1 | PROTEIN FRAGMENT COMPLEMENTATION ASSAYS TO DETECT BIOMOLECULAR INTERACTIONS | UNIVERSITE DE MONTREAL (CA) | 1998-08-06 | — | — | WO | disclosed |